Business Context and Reporting Period
Company: Prenetics Global Ltd (Prenetics)
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal Year Ended December 31, 2025
Business Overview: Prenetics is a Cayman Islands-based consumer health company. In 2025, the company executed a strategic pivot from a genomic testing focus to a consumer health and longevity platform centered on its flagship brand, IM8 (co-founded with David Beckham). The company divested its Diagnostics segment (ACT Genomics) and its low-margin logistics business (Europa 3PL) to streamline operations.
Key Financial Metrics
| Metric | 2025 | 2024 | YoY Change |
|---|---|---|---|
| Total Revenue (Continuing Ops) | $92.4 million | $15.9 million | +480% |
| IM8 Revenue | $60.1 million | $0.4 million | +16,156% |
| Gross Profit | $48.8 million | $9.3 million | +426% |
| Gross Margin | 52.8% | 58.2% | -540 bps |
| Net Loss (Continuing Ops) | $(36.2) million | $(38.4) million | -5.7% |
| Net Loss (Total) | $(40.0) million | $(49.8) million | -19.7% |
| Adjusted EBITDA Loss | $(13.9) million | $(17.7) million | +21.5% |
| Cash and Cash Equivalents | $32.1 million | $52.3 million | -38.6% |
| Digital Assets (Bitcoin) | $44.6 million | $0 | N/A |
Note: Revenue figures represent continuing operations only. Discontinued operations (ACT Genomics) generated a net loss of $3.7 million in 2025.
Material Changes vs. Prior Period
- Revenue Surge: Total revenue increased 480% year-over-year, driven almost entirely by the IM8 consumer health brand, which grew from $0.4 million to $60.1 million. The Prevention segment (CircleDNA) grew 25% to $12.9 million.
- Strategic Divestitures: The company disposed of ACT Genomics (Diagnostics) in October 2025, classifying it as discontinued operations. This eliminated a significant source of operational complexity and cash burn.
- Margin Compression: Consolidated gross margin decreased from 58.2% to 52.8%. This was primarily due to the inclusion of the lower-margin Europa distribution business (acquired in 2024) in the revenue mix. Management expects margins to improve to over 60% in 2026 following the divestiture of the Europa 3PL business.
- Digital Asset Strategy: The company initiated a digital asset treasury strategy in 2025, acquiring approximately 510 Bitcoin. This resulted in a $9.7 million unrealized fair value loss recognized in the income statement, though the assets remain on the balance sheet at $44.6 million.
- Non-Cash Gains/Losses: The income statement included a $36.7 million non-cash gain on warrant exchange and a $17.9 million non-cash fair value loss on warrant liabilities.
Guidance, Outlook, and Risks
Guidance and Outlook
- 2026 Revenue Guidance: Management projects IM8 revenue to reach between $180 million and $200 million in 2026.
- Profitability Target: The company targets Adjusted EBITDA profitability by Q4 2027, with a 2026 Adjusted EBITDA loss guidance of $(16) million to $(20) million.
- Capital Allocation: The board authorized a $40 million share repurchase program in March 2026. The company also completed a $44 million equity offering in October 2025.
Management Commentary
Management emphasizes a "subscription-first" business model for IM8, with approximately 80% of new customers opting for subscriptions. The company is leveraging AI for creative production and customer acquisition to reduce costs and improve efficiency. The strategic focus is entirely on scaling the IM8 brand and the complementary CircleDNA asset.
Risks and Contingencies
- Digital Asset Volatility: Significant exposure to Bitcoin price fluctuations, which can cause material volatility in reported earnings unrelated to core operations.
- Regulatory Environment: Operations in Hong Kong expose the company to potential regulatory changes regarding data security and cross-border data transfer, as well as risks under the Holding Foreign Companies Accountable Act (HFCAA).
- Brand and Marketing: Heavy reliance on high-profile brand ambassadors (e.g., David Beckham) and social media marketing channels creates reputational risks and dependency on third-party platforms.
- Liquidity: While cash reserves are $32.1 million, the company continues to incur net losses and relies on capital markets for funding growth.
Key Facts for Investor Verification
- IM8 Growth Sustainability: Verify the retention rates and customer lifetime value (LTV) of the IM8 subscription base to ensure the 480% revenue growth is sustainable beyond the initial launch phase.
- Digital Asset Accounting: Confirm the valuation methodology for Bitcoin holdings and the potential impact of future price declines on the company's equity and reported losses.
- Divestiture Proceeds: Track the realization of proceeds from the sale of ACT Genomics and the subsequent sale of the Insighta stake (completed Feb 2026) to assess actual cash inflows versus reported gains.
- Margin Trajectory: Monitor the gross margin improvement in 2026 following the divestiture of the low-margin Europa 3PL business to validate the ~60% margin target.
- Warrant Liability: Review the fair value assumptions for warrant liabilities, which caused a $17.9 million non-cash loss in 2025, as these can significantly distort GAAP profitability.